TABLE 2.
Oligonucleotides used in the study
| Oligonucleotide | Nucleotide sequence (5′→3′)a | Useb |
|---|---|---|
| p1 | CGATCCTGCTTTAACTGCTGTTGAAACTGGTGCTACTAT | VP1 |
| p2 | CGATAGTAGCACCAGTTTCAACAGCAGTTAAAGCAGGAT | VP1 |
| p3 | CTGAGAATTCAGTTACAGCAACCAACG | PCR |
| p4 | TTTAAAGCTTGTTTTTCCTAACAAAGGCC | PCR |
| p5 | CCATGGTACAATCAAGTTTAAAGAAATCTC | PCR |
| p6 | CCTGCTTTAACTGCTGTTGAAACTGGTGCTACTGCCGCCGATCAAACTGCTC | R-PCR, site II/VP1 |
| p7 | AGTAGCACCAGTTTCAACAGCAGTTAAAGCAGGCTTATCGCTTACCTTAGAACCTG | R-PCR, site II/VP1 |
| p8 | CCTGCTTTAACTGCTGTTGAAACTGGTGCTACTAATGATAAGGTTGCAGCTAACG | R-PCR, site III/VP1 |
| p9 | AGTAGCACCAGTTTCAACAGCAGTTAAAGCAGGAGCATCAGCTGTAGTCAATGC | R-PCR, site III/VP1 |
| p10 | TACCGAATTCGGGACAGGTGCTAGAGAC | PCR |
| p11 | AGTAGCACCAGTTTCAACAGCAGTTAAAGCAGGAGCCATAGTAGCCTTAGAAG | R-PCR, site IV/VP1 |
| p12 | CCTGCTTTAACTGCTGTTGAAACTGGTGCTACTAAGTTAGCTTCTTCAAAGAGTC | R-PCR, site IV/VP1 |
| p13 | GTATGAATTCGAAATGACTTCAGAAAAGG | PCR |
| p14 | GACAGGATCCATATAGAAGAAAAGGGC | PCR |
| p15 | CACAAAGCTTTGAAGAAGCAGCACTGTCC | PCR |
| p16 | CCAAGATCTAGTCTTATAACTATACTG | PCR |
| p17 | CAGATCCTCTTCTGAGATGAGTTTTTGTTCCTTATCGCTTACCTTAGAACCTG | R-PCR, site II/c-Myc |
| p18 | GAACAAAAACTCATCTCAGAAGAGGATCTGGCCGCCGATCAAACTGCTC | R-PCR, site II/c-Myc |
| p19 | GTTCGGTACCATCAACAAAGCTCACCTA | PCR |
| p20 | CTGAGGTACCTCTCTTTACTTGGGCCTTGC | PCR |
| p21 | CAGATCCTCTTCTGAGATGAG | PCR |
| p22 | TCATCTCAGAAGAGGATCTG | PCR |
| p23 | ACTATCCCGACCGCCTTAC | PCR |
| p24 | CGTAACTGCCATTGAAATAGACC | PCR |
| p25 | GAGATAAGAATTGTTCAAAGCTA | PCR |
| p26 | TGCAGGTACCGATTACAAAGGCTTTAAGC | PCR |
| P27 | CATGGGATCCCTGGTACACAAGTACTTGG | PCR |
| p28 | ATTTGAATTCAGCAGCATAGACTGTTGAG | PCR |
The epitope-encoding nucleotides are underlined.
R-PCR, recombinant PCR; VP1, a poliovirus type 3 VP1 epitope; c-Myc, an epitope from the human c-myc proto-oncogene; sites II to IV refer to the insertion sites of the epitope-encoding nucleotides in the slpA gene.